ClinicalTrials.gg
WithdrawnNCT06313996Updated Mar 18, 2026

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

A Phase 3 interventional study of Cyclophosphamide and Doxorubicin in Relapsed or Refractory Follicular Lymphoma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Primary conditionLymphoma, FollicularRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Follicular.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Replaced with another clinical trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb — 2 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · Bristol-Myers Squibb.

Enrollment
18th of 18
0 · median 61
Started
2024
with 4 others
Phase 3
4 of 23
1 open now
Registered
16th of 23
by date

Among the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 3, and was the 16th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

2 of the 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Lymphoma, Follicular by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.

Read the detailed description

The purpose of this phase III study is to evaluate the clinical benefit of liso-cel for the treatment of r/r FL by comparing it to standard of care therapy in patients with r/r FL, with progression-free survival (PFS) as the primary endpoint.

The primary objective is to demonstrate superiority of the Liso-cel treatment strategy over standard of care (SOC) therapy with respect to progression-free survival (PFS) determined by independent review committee (IRC) based on the Lugano response criteria.

Participants randomized to Arm A (Standard of Care) will receive RCHOP, BR, or R2 based on investigator choice and this has to be determined prior to randomization.

Participants randomized to Arm B (Liso-cel treatment) will receive a single infusion CAR-positive viable T-cells.

03

Conditions studied

  • Relapsed or Refractory Follicular Lymphoma

Browse trials for

Keywords

  • Lisocabtagene Maraleucel
  • Liso-cel
  • Follicular Lymphoma
04

In context

Lymphoma, Follicular Reclassified

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Lead sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.

First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have .
  • Participants must have previously been treated with certain defined anti-cancer therapies and their disease must have come back or must have not responded to the previous or last treatment.
  • Participants must have an (ECOG) performance status of 0 or 1.
  • Participants that have confirmed Follicular Lymphoma (FL) (Grade 1, 2, or 3a) corresponding to the most recent relapse prior to screening.
  • Participants that have FL, as assessed by the Investigator.
  • Participants that have received at least one prior line and no more than three including a combination of an anti-CD20 antibody and an alkylating agent.
  • Participants that received one prior line of systemic therapy are eligible if they present with high risk features.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any history of heart problems.
  • Participants must not have any bleeding disorders.
  • Participants must not have any Central Nervous System involvement by Follicular Lymphoma or other brain conditions.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Arm A

    Active Comparators: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) B-R (bendamustine and rituximab) R2 (rituximab and lenalidomide)

    Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Rituximab · Drug: Prednisone · Drug: Bendamustine · Drug: Lenalidomide

  • Experimental
    Arm B

    Lisocabtagene Maraleucel

    Drug: Fludarabine · Drug: Liso-cel

Interventions

07

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Defined as the time from randomization to death due to any cause or progressive disease (PD) per independent review committee (IRC) assessment using the Lugano 2014 Criteria, whichever occurs first

    Time frame: Up to 5 years from the last participant randomized

Secondary outcomes

  1. Complete response (CR)

    Defined as participants achieving a complete response per IRC assessment using the Lugano 2014 Criteria

    Time frame: Up to 5 years from the last participant randomized

  2. Overall survival (OS)

    Defined as the time from randomization to death due to any cause

    Time frame: Up to approximately 7 years

  3. Overall response (OR)

    Defined as participants achieving a response (CR or partial response (PR)) per IRC assessment using the Lugano 2014 Criteria

    Time frame: Up to 5 years from the last participant randomized

  4. Duration of response (DOR)

    Defined as the time from first response (CR or PR) per IRC assessment using the Lugano 2014 Criteria to PD or death due to any cause, whichever occurs first

    Time frame: Up to 5 years from the last participant randomized

  5. Event-free survival (EFS)

    Defined as the time from randomization to the first documentation of progressive disease (PD) per IRC assessed using the Lugano 2014 Criteria start of new anti-cancer therapy, or death due to any cause, whichever occurs first

    Time frame: Up to 5 years from the last participant randomized

  6. Time to next anti-cancer therapy (TTNLT)

    Defined as time from randomization to start of new anti-cancer therapy or death due to any cause, whichever occurs first

    Time frame: Up to 5 years from the last participant randomized

  7. PFS rate

    Time frame: Up to 5 years from the last participant randomized

  8. EFS rate

    Time frame: Up to 5 years from the last participant randomized

  9. OS rate

    Time frame: Up to approximately 7 years

  10. Progression-free survival on the next line of treatment (PFS-2)

    Defined as the time from randomization to death from any cause or tumor progression on next line treatment per Investigator assessment, whichever occurs first

    Time frame: Up to 5 years from the last participant randomized

  11. Number of participants with adverse events (AEs)

    Time frame: Up to 5 years from the last participant randomized

  12. Number of participants with adverse event of special interest (AESIs)

    Time frame: Up to 5 years from the last participant randomized

  13. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 5 years from the last participant randomized

  14. Number of participants with laboratory abnormalities

    Time frame: Up to 5 years from the last participant randomized

  15. Frequency and length of hospitalizations

    Time frame: Up to 5 years from the last participant randomized

  16. Number of participants with intensive care unit (ICU) inpatient days

    Time frame: Up to 5 years from the last participant randomized

  17. Number of participants with non-ICU inpatient days

    Time frame: Up to 5 years from the last participant randomized

  18. Mean change from baseline in key health-related quality of life (HRQoL) domains.

    Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20)

    Time frame: Up to 5 years from the last participant randomized

  19. Time to meaningful improvement/deterioration in key HRQoL domains.

    Key HRQoL Domains: Global health status/quality of life (GHS/QoL), fatigue, pain, physical functioning, role functioning, cognitive functioning from The European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ C30), and Symptom Burden and Physical Condition/Fatigue from the European Quality of Life Module Non-Hodgkin's Lymphoma Low-Grade 20 items (EORTC QLQ-NHL-LG20)

    Time frame: Up to 5 years from the last participant randomized

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Oct 2031, 90 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 15, 2024
StartEst.
Mar 29, 2024
Primary completionEst.
Oct 16, 2031
CompletionEst.
Oct 16, 2031
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06313996
Collaborators
Celgene Corporation
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Mar 29, 2024 (estimated)
Primary completion
Oct 16, 2031 (estimated)
Completion
Oct 16, 2031 (estimated)
Last update
Mar 18, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion